Long-Term Outlook for Women on GLP-1 Therapy Women can achieve significant and sustained weight loss on GLP-1 medications, but the timeline may be longer
The genes affected by semaglutide included markers of inflammation and plaque stability that are associated with leukocyte recruitment [e.g., interleukin-1 (IL-1) receptor antagonist, IL-6, monocyte chemoattractant protein (CCL2), OPN], leukocyte adhesion [selectin E, vascular cell adhesion molecule-1 (VCAM1)], leukocyte extravasation and plaque stability (e.g., MMP3, MMP13, CCL2), and plaque rupture and hemorrhage (CD163)
NoMedi-Cal Rx is excluding GLP-1 weight loss drugs effective January 1, 2026
Wharton S, Frietas P, Hjelmesth J, et al
51 KameokaJ.TanakaT.NojimaY.SchlossmanS